Amgen (XTER:AMG) Other Gross PPE : €5,522 Mil (As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Amgen Other Gross PPE?

Amgen's Other Gross PPE for the quarter that ended in Mar. 2024 was €5,522 Mil.

Amgen's quarterly Other Gross PPE declined from Sep. 2023 (€5,213 Mil) to Dec. 2023 (€4,414 Mil) but then increased from Dec. 2023 (€4,414 Mil) to Mar. 2024 (€5,522 Mil).

Amgen's annual Other Gross PPE increased from Dec. 2021 (€3,944 Mil) to Dec. 2022 (€4,422 Mil) but then declined from Dec. 2022 (€4,422 Mil) to Dec. 2023 (€4,414 Mil).

Amgen Other Gross PPE Historical Data

The historical data trend for Amgen's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Other Gross PPE Chart

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

4,094.10

3,907.79

3,944.45

4,421.70

4,413.52

Amgen Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial															5,099.64	5,106.04	5,212.53	4,413.52	5,521.84

Amgen Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Amgen (XTER:AMG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XTER:AMG) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMGN34:Brazil AMGN:Austria AMGN:Argentina

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.